---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-027504"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T06:11:22.976641+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Veru reports Q1 revenue $2.1M, cash $40.6M; FDA clears IND for enobosarm with GLP-1 for weight loss

## Summary
- Net revenue $2.1M (down from $2.5M YoY); gross profit $1.2M (up from $0.7M).
- Cash $40.6M at Dec 31, 2023, bolstered by $35.2M net proceeds from public offering.
- FDA cleared IND for enobosarm in combination with GLP-1 drugs to preserve muscle during weight loss.
- Phase 2b obesity study to start by April 2024; top-line results expected by end of calendar 2024.
- Enobosarm for metastatic breast cancer funding-dependent; sabizabulin COVID program paused without external funding.

## SEC filing metadata
- accession: 0001193125-24-027504
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312524027504/0001193125-24-027504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312524027504/d671709d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-027504
- JSON: https://secwatch.observer/filing/0001193125-24-027504.json
- Plain text: https://secwatch.observer/filing/0001193125-24-027504.txt

## Key facts
- Earnings Releases
  VERU INC. reported financial results for fiscal 2024 first quarter ended December 31, 2023.
  - Period: fiscal 2024 first quarter ended December 31, 2023
  - Result: reported results
  source text: On February 8, 2024, Veru Inc. issued a press release (the “Press Release”) announcing certain financial highlights for the quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/863894/000119312524027504/0001193125-24-027504-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.